CN103635204B - Cetp片段 - Google Patents

Cetp片段 Download PDF

Info

Publication number
CN103635204B
CN103635204B CN201280028674.1A CN201280028674A CN103635204B CN 103635204 B CN103635204 B CN 103635204B CN 201280028674 A CN201280028674 A CN 201280028674A CN 103635204 B CN103635204 B CN 103635204B
Authority
CN
China
Prior art keywords
seqidno
peptide
vaccine
cetp
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280028674.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN103635204A (zh
Inventor
S.布伦纳
M.格布哈特
E.比尔齐科瓦
C.朱诺
P.林茨迈耶-赫特
B.舒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affiris AG
Original Assignee
Affiris AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affiris AG filed Critical Affiris AG
Publication of CN103635204A publication Critical patent/CN103635204A/zh
Application granted granted Critical
Publication of CN103635204B publication Critical patent/CN103635204B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201280028674.1A 2011-06-10 2012-06-11 Cetp片段 Expired - Fee Related CN103635204B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11169481.6 2011-06-10
EP11169481A EP2532359A1 (en) 2011-06-10 2011-06-10 CETP fragments
PCT/EP2012/061038 WO2012168486A1 (en) 2011-06-10 2012-06-11 Cetp fragments

Publications (2)

Publication Number Publication Date
CN103635204A CN103635204A (zh) 2014-03-12
CN103635204B true CN103635204B (zh) 2016-03-30

Family

ID=44514130

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280028674.1A Expired - Fee Related CN103635204B (zh) 2011-06-10 2012-06-11 Cetp片段

Country Status (15)

Country Link
US (1) US9085636B2 (es)
EP (2) EP2532359A1 (es)
JP (1) JP6336901B2 (es)
KR (1) KR20140026390A (es)
CN (1) CN103635204B (es)
AU (1) AU2012266245B2 (es)
BR (1) BR112013022164A2 (es)
CA (1) CA2837767A1 (es)
DK (1) DK2717908T3 (es)
ES (1) ES2545458T3 (es)
IL (1) IL227821A0 (es)
MX (1) MX2013009521A (es)
RU (1) RU2014100115A (es)
SG (1) SG194425A1 (es)
WO (1) WO2012168486A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR111760A1 (es) 2017-05-19 2019-08-14 Novartis Ag Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002098915A2 (en) * 2001-06-07 2002-12-12 Genfit Compositions and methods for detecting or regulating cholesteryl ester transfer protein
WO2006133196A1 (en) * 2005-06-06 2006-12-14 Avant Immunotherapeutics, Inc. Modulation of cholesteryl ester transfer protein (cetp) activity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0618803A4 (en) 1991-12-19 1995-03-22 Southwest Found Biomed Res POLYPEPTIDE INHIBITING PROTEIN TRANSFER TO CHOLESTERYL ESTERS, ANTIBODIES AGAINST SYNTHETIC POLYPEPTIDE AND ANTI-ATHEROSCLEROSIS PROPHYLACTIC AND THERAPEUTIC TREATMENTS.
JPH09501186A (ja) 1994-11-12 1997-02-04 株式会社エルジ化学 コレステリルエステル運搬蛋白質阻害ペプチドおよびこれを含む動脈硬化症のための予防および治療剤
US6410022B1 (en) 1995-05-01 2002-06-25 Avant Immunotherapeutics, Inc. Modulation of cholesteryl ester transfer protein (CETP) activity
JP3580948B2 (ja) * 1995-05-02 2004-10-27 日本たばこ産業株式会社 ヒト由来ｃｅｔｐに反応性を有するモノクローナル抗体及びヒト由来ｃｅｔｐの定量方法
AT500835B1 (de) 2004-09-13 2007-12-15 Affiris Forschungs & Entwicklungs Gmbh Cholinestertransport-protein-mimotop als atherosklerose-medikament
WO2008125623A2 (en) 2007-04-13 2008-10-23 Novartis Ag Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (pcsk9)
AT505574B1 (de) 2007-08-10 2009-09-15 Affiris Forschungs & Entwicklungs Gmbh Mimotope zur behandlung von atherosklerose
AT507604A1 (de) 2008-11-19 2010-06-15 Affiris Forschungs & Entwicklungs Gmbh Behandlung von atherosklerose
MX2012002639A (es) 2009-09-03 2012-03-14 Pfizer Vaccines Llc Vacuna de pcsk9.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002098915A2 (en) * 2001-06-07 2002-12-12 Genfit Compositions and methods for detecting or regulating cholesteryl ester transfer protein
WO2006133196A1 (en) * 2005-06-06 2006-12-14 Avant Immunotherapeutics, Inc. Modulation of cholesteryl ester transfer protein (cetp) activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
抗动脉粥样硬化疫苗的制备及免疫学研究;孙云霄等;《药物生物技术》;20081231;411-417 *

Also Published As

Publication number Publication date
MX2013009521A (es) 2013-10-01
NZ613913A (en) 2015-07-31
AU2012266245B2 (en) 2017-02-02
RU2014100115A (ru) 2015-07-20
EP2532359A1 (en) 2012-12-12
WO2012168486A1 (en) 2012-12-13
US9085636B2 (en) 2015-07-21
SG194425A1 (en) 2013-12-30
AU2012266245A1 (en) 2013-08-29
DK2717908T3 (en) 2015-08-03
US20140147456A1 (en) 2014-05-29
CN103635204A (zh) 2014-03-12
IL227821A0 (en) 2013-09-30
EP2717908A1 (en) 2014-04-16
CA2837767A1 (en) 2012-12-13
JP6336901B2 (ja) 2018-06-06
EP2717908B1 (en) 2015-07-22
KR20140026390A (ko) 2014-03-05
ES2545458T3 (es) 2015-09-11
JP2014519512A (ja) 2014-08-14
BR112013022164A2 (pt) 2018-06-26

Similar Documents

Publication Publication Date Title
JP6054400B2 (ja) ワクチン
JP6199036B2 (ja) 自己タンパク質に対する体液性免疫応答に関わる腫瘍ワクチン接種
US20240197844A1 (en) Peptide vaccines usable for hypercholesterolemia related diseases
Mao et al. Intramuscular immunization with a DNA vaccine encoding a 26-amino acid CETP epitope displayed by HBc protein and containing CpG DNA inhibits atherosclerosis in a rabbit model of atherosclerosis
CN103635204B (zh) Cetp片段
Gerloni et al. Activation of CD4 T cells by somatic transgenesis induces generalized immunity of uncommitted T cells and immunologic memory
CN105859837B (zh) 胆固醇酯转运蛋白抗原肽和融合蛋白以及其组合物和应用
NZ613913B2 (en) Cetp fragments

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1193562

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160330

Termination date: 20190611

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1193562

Country of ref document: HK